Finance

Lists
ROVI:BME
Laboratorios Farmaceuticos ROVI SA
€57,40
+0,09%
(+0,050) 1D
2 Okt., 17:36:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ROVI...
Open
€57,10
High
€57,90
Low
€56,55
Mkt. cap
2,87 mjd
Avg. vol.
88,03 k
Volume
85,22 k
Dividend
1,67%
Quarterly dividend
€0,24
Ex-dividend date
13 Jul. 2026
P/E ratio
15,89
52-wk high
€86,70
52-wk low
€53,10
EPS
€3,61
Shares outstanding
51,24 m
No. of employees
2 k
Open
€57,10
High
€57,90
Low
€56,55
Mkt. cap
2,87 mjd
Avg. vol.
88,03 k
Volume
85,22 k
Dividend
1,67%
Quarterly dividend
€0,24
Ex-dividend date
13 Jul. 2026
P/E ratio
15,89
52-wk high
€86,70
52-wk low
€53,10
EPS
€3,61
Shares outstanding
51,24 m
No. of employees
2 k
News stories
From web sources and news partners
Profile
Laboratorios Farmaceuticos Rovi SA is a Spanish pharmaceutical company. The company is a member of the IBEX 35 stock market index. Wikipedia
About Laboratorios Farmaceuticos ROVI SA
CEO-
Employees2,47 k
Founded1946
Headquarters-
SectorPharmaceutical industry
Websiterovi.es
Last report
23 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€1,46 / -
0,00%miss
Revenue / Est. (EUR)
344,16 m / 179,82 m
+91,39%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
210,47 m
218,42 m
152,49 m
191,67 m
Cost of goods sold
62,66 m
90,33 m
59,61 m
60,04 m
Cost of revenue
62,66 m
90,33 m
59,61 m
60,04 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34,66 m
55,40 m
38,04 m
47,22 m
Operating expense
79,83 m
73,16 m
83,00 m
113,58 m
Total operating expenses
142,49 m
163,49 m
142,61 m
173,62 m
Operating income
67,98 m
54,93 m
9,89 m
18,05 m
Other non operating income
8,35 m
3,80 m
2,32 m
10,64 m
EBT including unusual items
75,70 m
57,94 m
12,29 m
89,28 m
EBT excluding unusual items
75,70 m
57,94 m
12,29 m
26,93 m
Income tax expense
17,68 m
15,29 m
2,84 m
14,35 m
Effective tax rate
23,36%
26,39%
23,11%
16,07%
Other operating expenses
37,70 m
9,61 m
36,79 m
56,55 m
Net income
58,03 m
42,68 m
9,48 m
75,00 m
Net profit margin
27,57%
19,54%
6,22%
39,13%
Earnings per share
-
-
-
-
Interest and investment income
86,00 k
-
403,00 k
474,00 k
Interest expense
-757,00 k
-767,00 k
-782,00 k
-1,97 m
Net interest expenses
-671,00 k
-767,00 k
-379,00 k
-1,50 m
Depreciation and amortization charges
7,47 m
8,16 m
8,17 m
9,81 m
EBITDA
79,21 m
55,10 m
18,05 m
23,60 m
Gain or loss from assets sale
-
14,00 k
1,77 m
-2,00 k
AI content may include mistakes. Learn more
Google-programme